Jiangsu Hillgene Biopharma
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A specialized CDMO and QC kit provider accelerating the development and manufacturing of cell and gene therapies, with global GMP facilities.
Oncology
Technology Platform
Integrated CDMO platform for serum-free lentiviral vector and cell therapy manufacturing, coupled with a proprietary suite of ELISA/qPCR-based quality control test kits (BlueKit) for residual impurity detection.
Opportunities
Capitalizing on the rapid growth of the cell and gene therapy market, especially in China, by providing integrated CDMO and QC solutions that can reduce client timelines and costs.
Expansion into in vivo gene therapy CDMO services and broader international client acquisition present additional growth avenues.
Risk Factors
Faces intense competition from larger, established global CDMOs and is dependent on the clinical success and market adoption of client therapies.
Regulatory hurdles for cross-border manufacturing and potential pricing pressures in the CDMO sector are additional challenges.
Competitive Landscape
Competes with global CGT CDMOs (e.g., Lonza, Catalent, WuXi AppTec) and analytical service providers. Differentiates through deep cell therapy specialization, an integrated 'CDMO + QC kits' model, and a cost-competitive operational base in China with strategic international facilities for global reach.